Know Labs - KNWN STOCK NEWS

Know Labs (OTC: KNWND), a leader in Radio Frequency Dielectric Spectroscopy (RFDS) sensor technology, has announced updates to its intellectual property portfolio. The company currently holds 325 patents (issued, pending, and in process) and has revealed a library of 1,022 trade secrets codified through the Tangibly platform.

According to an independent analysis by PatSnap, Know Labs' patent portfolio ranks first globally in specific categories of medical diagnostics and industrial process control. The company's IP strategy involves both patents and trade secrets, with the latter being disclosed publicly for the first time as part of their Know Labs Technology Licensing (KTL) initiative.

The slight reduction from previously reported 332 patent assets is attributed to combining provisional patents into utility patents and strategic abandonment of less critical pending patents. The company emphasizes that both patents and trade secrets will continue to grow as innovation progresses.

Know Labs (KNWN) has announced the cancellation of its Special Meeting of Stockholders that was scheduled for March 7, 2025. The meeting was originally intended to seek approval for a reverse stock split. This cancellation follows the company's recent implementation of a 1-for-40 reverse stock split of its authorized and outstanding common stock on February 18, 2025, which became effective February 19, 2025. The company noted that this reverse split did not require stockholder approval.

Know Labs, which recently moved from NYSE American (KNW) to OTC Pink Markets (KNWN), is known for its work in radio frequency dielectric spectroscopy (RFDS) technology.

Know Labs (KNWN) has announced a 1-for-40 reverse stock split of its common stock, effective February 19, 2025. The company's stock will temporarily trade under 'KNWND' for 20 days before reverting to 'KNWN' on the OTC Pink Market. This move follows the company's delisting from NYSE American due to bid prices falling below $0.10.

The company is currently appealing the delisting decision to the NYSE American Listings Qualifications Panel, with trading suspended during the appeal process. The reverse split was implemented by the Board of Directors as part of efforts to regain NYSE American listing compliance. The company expects near-term revenues from its recently announced Know Labs Technology Licensing initiative while continuing its focus on blood glucose monitoring development.

Know Labs (KNWN) reported Q1 FY2025 financial results, showing a net loss of $4.67 million, up 35.4% from $3.45 million in Q1 FY2024. The company recorded a non-cash charge of $2.45 million related to stock-based compensation, debt extinguishment, warrant repricing, and debt issuance costs.

R&D expenses decreased 46.1% to $802,000, while SG&A expenses dropped 2% to $1.97 million. Cash and equivalents stood at $1.03 million as of December 31, 2024, down from $3.11 million on September 30, 2024. The company closed a $300,000 registered direct offering and believes it has sufficient funds to operate until April 30, 2025.

Shareholder equity was negative $3.91 million, and the company's auditors included a going concern warning in their opinion.

Know Labs (KNWN) has announced it will host a webcast on February 14, 2025, at 1:30 PM PT to discuss its first quarter fiscal year 2025 business updates and financial results for the period ended December 31, 2024. The company, which recently moved from NYSE American to OTC Markets, specializes in radio frequency dielectric spectroscopy (RFDS) for non-invasive medical diagnostic technology and has launched the Know Labs Technology Licensing (KTL) initiative.

The live audio webcast will be accessible to media and investors at https://ir.knowlabs.co starting at 1:15 PM PT, with a replay available afterward on the company's website.

Know Labs (OTC: KNWN) has announced the launch of a structured client engagement process for Know Labs Technology Licensing (KTL), focusing on the integration of their Radio Frequency Dielectric Spectroscopy (RFDS) technology. The initiative builds upon their portfolio of over 300 global patents and includes their patent-pending e-RFDS™ digital watermark technology for authentication and security.

The company has introduced a comprehensive five-phase Global Innovation Engagement Model, developed in partnership with ipCapital Group. The model includes licensee onboarding, data collection, AI modeling, laboratory support, and IP development. The new program features structured documentation, educational materials, and a dedicated online portal for potential partners.

KTL's offering includes various licensing options such as field of use, non-exclusive, and exclusive licenses, aimed at corporations, universities, and research institutions seeking to integrate RFDS technology into their R&D and innovation initiatives.

Know Labs (KNWN) has filed an appeal against NYSE American's decision to delist the company due to its stock price falling below $0.10. During the appeal process, trading of Know Labs stock on NYSE American will be suspended, and the company has transitioned to trading on the OTC Markets under the symbol 'KNWN' effective January 29, 2025.

The company, which specializes in radio frequency dielectric spectroscopy (RFDS), recently initiated a licensing program through Know Labs Technology Licensing (KTL) and continues to advance its proprietary technology. Their primary focus remains on developing non-invasive diagnostics, particularly blood glucose monitoring, which will require FDA clearance before market introduction.

CEO Ron Erickson emphasized that despite the NYSE situation, the company has successfully reduced overhead, received peer-reviewed recognition, and maintains optimism about near-term licensing opportunities and revenue generation.

Know Labs (NYSE American: KNW) announced that NYSE Regulation is initiating delisting proceedings due to the company's bid price falling under $.10, according to Section 1003(f)(v) of the NYSE American Company Guide. The company's stock will be suspended from NYSE American trading while Know Labs works on compliance measures and appeals the delisting determination.

Effective January 29, 2025, the company's stock will trade on the OTC Markets under the symbol 'KNWN'. CEO Ron Erickson emphasized that this development comes at a time when the company has initiated a licensing program, received peer-reviewed recognition, reduced overhead, and continued advancing its proprietary radio frequency dielectric spectroscopy (RFDS) technology. The company maintains its focus on developing non-invasive diagnostics, particularly blood glucose monitoring.

Know Labs, Inc. (OTCQB: KNWN) has received approval to uplist to the NYSE American Exchange, changing its ticker from 'KNWN' to 'KNW' starting September 16, 2022. This uplisting is part of an underwritten public offering of the company’s common stock. Ron Erickson, Chairman of Know Labs, stated this milestone reflects the team's dedication to developing a non-invasive FDA-cleared blood glucose monitoring device. The company’s Bio-RFID technology aims to revolutionize medical diagnostics by providing real-time glucose level monitoring.